Abstract
To the Editor: The MARIPOSA trial by Cho et al. (Oct. 24 issue)1 investigated the efficacy and safety of amivantamab–lazertinib as compared with osimertinib in patients with EGFR (epidermal growth factor receptor)–mutated advanced non–small-cell lung cancer (NSCLC). Amivantamab–lazertinib led to significantly longer median progression-free survival than osimertinib (23.7 vs. 16.6 months; hazard ratio for disease progression or death, 0.7; P<0.001); overall survival could not be estimated because the numbers of deaths in the two trial groups were less than anticipated. However, amivantamab–lazertinib was associated with considerable toxic effects, with grade 3 adverse events occurring in 75% of the patients in the .
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call